SCHEMBL506661

SCHEMBL506661

ON=Cc1ccc(CCl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
MAPT P10636 3/20 0.48
RAB9A P51151 5/20 0.47
NPC1 O15118 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
KDM4E B2RXH2 2/20 0.47
GAA P10253 1/20 0.47
KMT2A Q03164 5/20 0.47
MEN1 O00255 3/20 0.44
ACHE P22303 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.41
NFKB1 P19838 2/20 0.40
NFKB2 Q00653 2/20 0.40
RELA Q04206 2/20 0.40
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL506660 1.00 ALDH1A1 (0.48) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL4021653 0.83 RAB9A (0.45) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL4021648 0.83 RAB9A (0.45) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL13613577 0.81 KMT2A (0.50) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL4275683 0.80 KMT2A (0.64) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL27198359 0.80 KMT2A (0.64) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL5668373 0.80 KMT2A (0.64) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL4275687 0.80 KMT2A (0.64) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL4619336 0.79 RAB9A (0.49) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL4619341 0.79 RAB9A (0.49) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2751099-B1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMA (US) 2017-06-14 EP disclosed
US-9630956-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-04-25 US disclosed
US-8853217-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-10-07 US disclosed
US-8846686-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-30 US disclosed
CN-103958507-A Compounds useful as inhibitors of ATR kinase VERTEX PHARMA 2014-07-30 CN disclosed
EP-2751099-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2014-07-09 EP disclosed
CN-103228651-A Compounds useful as inhibitors of atr kinase VERTEX PHARMA 2013-07-31 CN disclosed
US-20130096139-A1 Compounds Useful as Inhibitors of ATR Kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-18 US disclosed
US-20130089625-A1 Compounds Useful as Inhibitors of ATR Kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-11 US disclosed
WO-2013049722-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-04 WO disclosed
WO-2013049720-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-04 WO disclosed
US-20130041000-A1 NOVEL AZOLE COMPOUND AJINOMOTO CO., INC. (JP) 2013-02-14 US disclosed
US-20120027874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-02 US disclosed
US-20090170911-A1 NOVEL AZOLE COMPOUND AJINOMOTO CO. INC (JP) 2009-07-02 US disclosed
US-7517996-B2 Azole compound AJINOMOTO CO., INC. (JP) 2009-04-14 US disclosed
US-20060194850-A1 Novel azole compound AJINOMOTO CO. INC (JP) 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170911-A1 NOVEL AZOLE COMPOUND LPAR1, LPAR2, LPAR3 ALDH1A1 1467/4885MAPT 4817/4885RAB9A 2139/4885
US-20120027874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 ALDH1A1 3898/4885MAPT 2975/4885RAB9A 2945/4885
US-20130096139-A1 Compounds Useful as Inhibitors of ATR Kinase ATR, CHEK1, CHEK2 ALDH1A1 4137/4885MAPT 2700/4885RAB9A 2529/4885
US-20130041000-A1 NOVEL AZOLE COMPOUND LPAR1, LPAR2, LPAR3 ALDH1A1 1467/4885MAPT 4817/4885RAB9A 2139/4885
US-20060194850-A1 Novel azole compound LPAR1, LPAR2, LPAR3 ALDH1A1 1467/4885MAPT 4817/4885RAB9A 2139/4885
US-20130089625-A1 Compounds Useful as Inhibitors of ATR Kinase ATR, CHEK1, MAP3K1 ALDH1A1 3886/4885MAPT 2922/4885RAB9A 2593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.